Unjha Formulations Ltd
₹ 16.4
-4.94%
27 Jan
- close price
About
Incorporated in 1991, Unjha Formulations Ltd manufactures and sells Isabgol (Psyllium) Ayurvedic formulations.
Key Points
- Market Cap ₹ 7.32 Cr.
- Current Price ₹ 16.4
- High / Low ₹ 18.0 / 8.24
- Stock P/E 13.3
- Book Value ₹ 6.16
- Dividend Yield 0.00 %
- ROCE 21.0 %
- ROE 12.2 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 31.2 to 18.0 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 2.97% over past five years.
- Promoter holding is low: 36.9%
- Company has a low return on equity of 11.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4.39 | 5.87 | 4.92 | 6.56 | 8.84 | 10.36 | 12.23 | 11.30 | 11.28 | 10.59 | 9.96 | 14.16 | 15.28 | |
4.19 | 5.71 | 4.75 | 6.39 | 8.65 | 10.00 | 11.86 | 10.96 | 10.98 | 10.34 | 9.83 | 13.84 | 14.61 | |
Operating Profit | 0.20 | 0.16 | 0.17 | 0.17 | 0.19 | 0.36 | 0.37 | 0.34 | 0.30 | 0.25 | 0.13 | 0.32 | 0.67 |
OPM % | 4.56% | 2.73% | 3.46% | 2.59% | 2.15% | 3.47% | 3.03% | 3.01% | 2.66% | 2.36% | 1.31% | 2.26% | 4.38% |
0.02 | 0.00 | 0.00 | 0.02 | 0.09 | 0.08 | 0.11 | 0.04 | 0.10 | 0.26 | 0.22 | 0.19 | 0.13 | |
Interest | 0.02 | 0.01 | 0.01 | 0.00 | 0.01 | 0.10 | 0.10 | 0.02 | 0.01 | 0.12 | 0.17 | 0.13 | 0.06 |
Depreciation | 0.08 | 0.07 | 0.07 | 0.07 | 0.09 | 0.08 | 0.09 | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.15 |
Profit before tax | 0.12 | 0.08 | 0.09 | 0.12 | 0.18 | 0.26 | 0.29 | 0.26 | 0.30 | 0.31 | 0.10 | 0.30 | 0.59 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.67% | |
Net Profit | 0.12 | 0.08 | 0.09 | 0.12 | 0.17 | 0.26 | 0.30 | 0.26 | 0.30 | 0.31 | 0.10 | 0.25 | 0.55 |
EPS in Rs | 0.27 | 0.18 | 0.20 | 0.27 | 0.38 | 0.58 | 0.67 | 0.58 | 0.67 | 0.69 | 0.22 | 0.56 | 1.23 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 3% |
3 Years: | 8% |
TTM: | 32% |
Compounded Profit Growth | |
---|---|
10 Years: | 12% |
5 Years: | -4% |
3 Years: | -6% |
TTM: | 2850% |
Stock Price CAGR | |
---|---|
10 Years: | 19% |
5 Years: | 4% |
3 Years: | 38% |
1 Year: | 48% |
Return on Equity | |
---|---|
10 Years: | 22% |
5 Years: | 15% |
3 Years: | 12% |
Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | |
Reserves | -4.49 | -4.45 | -4.37 | -4.26 | -4.09 | -3.83 | -3.54 | -3.27 | -2.97 | -2.67 | -2.56 | -2.31 | -1.72 |
2.29 | 0.26 | 0.00 | 0.00 | 0.40 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | |
2.95 | 2.20 | 2.61 | 3.54 | 2.51 | 2.28 | 2.79 | 2.75 | 2.15 | 1.90 | 1.61 | 1.28 | 1.67 | |
Total Liabilities | 5.23 | 2.49 | 2.72 | 3.76 | 3.30 | 2.93 | 3.78 | 3.96 | 3.66 | 3.71 | 3.53 | 3.45 | 4.46 |
1.12 | 1.09 | 1.03 | 1.10 | 1.09 | 1.03 | 1.22 | 1.16 | 1.12 | 1.14 | 1.12 | 1.07 | 1.10 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
4.11 | 1.40 | 1.69 | 2.66 | 2.21 | 1.90 | 2.56 | 2.80 | 2.54 | 2.57 | 2.41 | 2.38 | 3.36 | |
Total Assets | 5.23 | 2.49 | 2.72 | 3.76 | 3.30 | 2.93 | 3.78 | 3.96 | 3.66 | 3.71 | 3.53 | 3.45 | 4.46 |
Cash Flows
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.19 | 2.10 | 0.49 | 0.53 | -0.70 | 0.41 | 0.39 | 0.14 | -0.12 | 0.39 | -0.70 | 0.28 | |
-0.02 | -0.03 | -0.02 | -0.13 | -0.09 | -0.02 | -0.28 | 0.06 | 0.04 | -0.10 | -0.06 | -0.02 | |
-0.17 | -2.07 | -0.27 | -0.02 | 0.40 | -0.40 | 0.05 | -0.05 | 0.23 | 0.00 | 0.00 | 0.00 | |
Net Cash Flow | 0.00 | 0.00 | 0.20 | 0.38 | -0.38 | -0.01 | 0.15 | 0.15 | 0.16 | 0.29 | -0.77 | 0.26 |
Ratios
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 276.04 | 39.80 | 49.71 | 50.63 | 28.08 | 28.54 | 19.40 | 25.19 | 43.36 | 39.64 | 35.91 | 18.04 |
Inventory Days | 37.72 | 23.50 | 39.21 | 50.22 | 35.62 | 22.76 | 40.83 | 39.40 | 22.92 | 21.37 | 55.60 | 34.08 |
Days Payable | 327.28 | 161.57 | 243.64 | 250.41 | 122.48 | 94.35 | 98.20 | 106.22 | 87.50 | 82.79 | 77.35 | 39.81 |
Cash Conversion Cycle | -13.52 | -98.27 | -154.73 | -149.55 | -58.78 | -43.06 | -37.97 | -41.63 | -21.22 | -21.79 | 14.16 | 12.31 |
Working Capital Days | 76.49 | -64.05 | -100.89 | -95.14 | -30.14 | -28.19 | -24.17 | -21.96 | -8.41 | -9.31 | 22.72 | 17.27 |
ROCE % | 5.82% | 7.00% | 50.00% | 72.73% | 37.62% | 50.00% | 47.56% | 25.45% | 22.79% | 25.90% | 14.48% | 21.03% |
Documents
Announcements
- Board Meeting Intimation for Board Meeting - Date: 10.02.2023 ( Un-Audited Financial Results For The Nine Month Ended On 31.12.2022) Ref: Clause 29(1)(A) Of The Listing Agreement 12 Jan
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Jan - Sub :Certificate Under Regulation 74 (5) Of The SEBI ( Depositiories And Participants ) Regulations , 2018 For Quarter Ended and 9Month Ended On 31.12.2022
-
Clarification sought from Unjha Formulations Ltd
20 Dec 2022 - Exchange has sought clarification from Unjha Formulations Ltd on December 19, 2022 with reference to significant movement in price, in order to ensure that investors …
- Structural Digital Database (SDD) Compliance Certificate Under SEBI (PIT) Regulations For The Quarter Ended 30/09/2022 15 Nov 2022
- Publish Un-Audited Financial Results For The Quarter And Half Year Ended As On 30/09/2022 11 Nov 2022
Business Profile:[1]
Company is G.M.P. certified for manufacturing & exporting of Isabgol (Psyllium) Ayurvedic formulations products. Company's parent company M/S Urvesh Ltd. is a 100% EOU
which is also engaged in export of
Isabgol Husk & Isabgol Powder.